IP Library Granted Patent US 8,569,076
Granted Patent B2
US 8,569,076 · App. 12/417,353 · Granted Oct 29, 2013

Method for serologic agglutination and other immunoassays performed in a thin film fluid sample

Inventors: Stephen C. Wardlaw (Lyme, CT); Robert A. Levine (Guilford, CT)
Assignee: Abbott Point of Care, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,569,076
App. No.
12/417,353
Granted
Oct 29, 2013
Kind
B2
Abstract

A method and system for performing a serological agglutination assay in a liquid sample. The system provides a simple method for creating an in-situ sample/reagent admixture within a sample analysis chamber without the use of any precision fluid-handling components.

Claims (11)

1. A method for performing a serologic agglutination assay for one or more target analyte antibodies in a liquid sample, said method comprising the steps of:

a) providing a thin planar chamber having opposed planar surfaces, at least one of which is transparent, which chamber has a height that is equal to or less than 20 μm;

b) placing an effective amount of detectable first particles in said planar chamber, said first particles containing on their surfaces an antigen against which the target analyte antibodies are directed;

c) placing control particles, similar in size and shape to said first particles, in said chamber, said control particles differing from said first particles in color, and said control particles being devoid of said antigens, and disposing a volume of sample within the thin planar chamber such that at least a portion of the sample contacts both opposed planar surfaces of the chamber;

d) allowing or causing said detectable first particles and said sample to admix with each other whereby said target analyte antibodies, when present, will cause agglutination of said detectable first particles;

e) electronically imaging or scanning said admixture to detect individual aggregates of particles by analysis of patterns of pixel intensity resulting from aggregation of detected particles; and

f) determining the presence or absence of significant particle agglutination by comparing signals of any aggregated first particles with signals of any aggregated control particles.

2. The method of claim 1 wherein the detection of presence of agglutination of particles is performed by measuring pixel areas of agglutinated first particles with pixel areas containing any agglutinated control particles.

3. The method of claim 1 wherein the detection of agglutination of particles is performed by determining the percentage of particles of any given type that are aggregated or clumped.

4. The method of claim 1 wherein there are more than one class of separately distinguishable detectable first particles, each class containing different antigens so that multiple assays may be simultaneously performed in the same sample chamber.

5. The method of claim 1 wherein said first particles and said control particles are differentially marked so as to be distinguishable one from the other.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2009
From: WARDLAW, STEPHEN C.; LEVINE, ROBERT` A.
To: ABBOTT POINT OF CARE, INC.
Reel/Frame 022860/0600 →
Continuity (7)
Provisional Application 61041784 · Apr 2, 2008
Provisional Application 61041791 · Apr 2, 2008
Provisional Application 61041790 · Apr 2, 2008
Provisional Application 61041794 · Apr 2, 2008
Provisional Application 61041797 · Apr 2, 2008
Provisional Application 61043571 · Apr 9, 2008
Related Publication 20090253218A1 · Oct 8, 2009